Farkas A, Conrad C, Tonel G, Borbenyi Z, Kemeny L, Dobozy A, Nestle F O
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Skin Pharmacol Physiol. 2006;19(3):124-31. doi: 10.1159/000092592. Epub 2006 Apr 6.
Recent progress in the approach towards immunotherapy of cancer consists in molecular definition of tumor antigens, new tools for phenotypical and functional characterization of tumor-specific effector cells and clinical use of novel adjuvants for optimal stimulation of a cancer-specific immune response such as dendritic cells. In spite of these advances and immunological as well as clinical responses in selected patients, mechanisms involved in dendritic-cell-based cancer immunotherapy are still poorly understood. Therefore, a standardized study design and small pilot trials are needed to explore open scientific questions in future clinical trials. This review focuses on the different parameters of dendritic cell biology relevant to cancer immunotherapy and on innovative approaches to hopefully enhance the efficacy of dendritic cell vaccination.
癌症免疫治疗方法的最新进展包括肿瘤抗原的分子定义、用于肿瘤特异性效应细胞表型和功能表征的新工具，以及新型佐剂的临床应用，以最佳刺激癌症特异性免疫反应，如树突状细胞。尽管取得了这些进展，并且在部分患者中出现了免疫和临床反应，但基于树突状细胞的癌症免疫治疗所涉及的机制仍知之甚少。因此，需要标准化的研究设计和小型试点试验，以在未来的临床试验中探索尚未解决的科学问题。本综述重点关注与癌症免疫治疗相关的树突状细胞生物学的不同参数，以及有望提高树突状细胞疫苗接种疗效的创新方法。
